The US FTC approves a final order settling charges that a merger between two pharmaceutical companies harmed competition in the markets for an antibiotic used to treat infections and an oral steroid product used to treat inflammation (ANI Pharmaceuticals / Novitium Pharma)

FTC Approves Final Order Requiring Generic Drug Marketers ANI Pharmaceuticals, Inc. and Novitium Pharma LLC to Divest Rights and Assets to Generic Sulfamethoxazole-Trimethoprim Oral

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.